A recent study indicates that individuals who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional lifestyle plans.
Research printed in a major health publication points out that while obese individuals can lose a large proportion of their body weight while on the medication, the mass is regained at an average rate of 0.8 kg per month once they quit.
"People using these drugs should be cognizant of the danger of fast weight regain when the medication concludes," stated researcher Dr. Susan Jebb.
That rate of regain suggests a return to pre-treatment weight in about one and a half years.
Weighing Approaches
The research, which examined 37 of trials involving over 9,000 of patients, compared the outcomes of the injectable medications with conventional dieting.
The team point out that individuals who lose weight through diet and exercise generally experience a slower creep back—around 100 grams monthly—once they finish.
Understanding the Fast Rebound
Nutrition scientists suggest the mode of action of the jabs explains the amplified regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels several times higher than normal may cause the body to generate a reduced amount of its own natural hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication leads to appetite is uncontrolled, making excessive eating far more likely."
A Chronic Issue?
Health authorities recommend the injections for individuals with weight-linked medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians argue that, given the significant potential of relapse, the treatment is often long-term.
This opinion is supported by drug manufacturers, who note that the results "highlight the persistent nature of excess weight," akin to managing conditions like hypertension.
Patient Testimonies
Users who have discontinued the medication explain a intense return of cravings.
"I experienced a switch activating and I was suddenly ravenous," recalled one woman.
This difficulty is exacerbated if individuals have not established permanent dietary or behavioural modifications during therapy.
Widespread Interest
Figures suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is more common among females than males.
- The middle-aged age group shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are potent tools for weight loss, they are not a magic solution and long-term success likely depends on integrated lifestyle support.
